Structure

InChI Key LJRDOKAZOAKLDU-UDXJMMFXSA-N
Smile NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O.O=S(=O)(O)O
InChI
InChI=1S/C23H45N5O14.H2O4S/c24-2-7-13(32)15(34)10(27)21(37-7)41-19-9(4-30)39-23(17(19)36)42-20-12(31)5(25)1-6(26)18(20)40-22-11(28)16(35)14(33)8(3-29)38-22;1-5(2,3)4/h5-23,29-36H,1-4,24-28H2;(H2,1,2,3,4)/t5-,6+,7+,8-,9-,10-,11-,12+,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23+;/m1./s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C23H47N5O18S
Molecular Weight 713.71
AlogP -8.86
Hydrogen Bond Acceptor 19.0
Hydrogen Bond Donor 13.0
Number of Rotational Bond 9.0
Polar Surface Area 347.32
Molecular species BASE
Aromatic Rings 0.0
Heavy Atoms 42.0

Pharmacology

Action Mechanism of Action Reference
INHIBITOR Bacterial 70S ribosome inhibitor PubMed DailyMed

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Leishmaniasis, Visceral 3 D007898 ClinicalTrials
Leishmaniasis 3 D007896 ClinicalTrials
Osteomyelitis 0 D010019 ClinicalTrials

Related Entries

Scaffolds

Parent

Adverse Reactions

System Organ Classification (SOC)
Relative Frequency (%)
Gastrointestinal disorders
21.21
Nervous system disorders
21.21
Ear and labyrinth disorders
12.12
General disorders and administration site conditions
12.12
Metabolism and nutrition disorders
9.09
Renal and urinary disorders
9.09
Vascular disorders
6.06
Cardiac disorders
3.03
Infections and infestations
3.03
Surgical and medical procedures
3.03

Cross References

Resources Reference
ChEMBL CHEMBL2206196
EPA CompTox DTXSID5047829
FDA SRS 845NU6GJPS
PubChem 441375
SureChEMBL SCHEMBL3355